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Prostate cancer is the second most common cancer worldwide in males and fifth most common 
cancer overall. Androgen deprivation therapy has been the standard treatment for prostate 
cancer. Androgen deprivation therapy involves surgical castration or medical castration. Medical 
castration is achieved by the use of LHRH agonist or antagonists. Medical castration combined 
with androgen receptor antagonists is called combined androgen blockade. Prostate cancer 
transforms to chemical castration resistant prostate cancer by the use of androgen deprivation 
therapy. Development of better treatment regime for prostate cancer is much needed.   
Two novel non-steroidal androgen receptor antagonists FL 442 AB and its nitro analogue FL 425 AB 
were selected to evaluate their oxidative metabolism and inhibition potential aspects. Oxidative 
metabolism of FL 442 AB and FL 425 AB were studied in-vitro to check their stability profile and 
level of formed metabolites under CYP incubation conditions. Oxidative metabolites of FL 442 AB 
and FL 425 AB were evaluated in-vitro using LNCAP and VCAP prostate cancer cell cultures to 
check their antagonistic response. Three inhibition experiments were performed to find out the 
inhibition of hepatic coumarin 7-hydroxylation (CYP 2A6), 7-ethoxyresorufin O-deethylation (CYP 
1A2), 7-benzyl 4-trifluoromethylcoumarin (CYP 3A4) by FL 442 AB and FL 425 AB and IC50 values 
were calculated. Results showed that FL 442 AB and FL 425 AB had anti androgenic activity and 
they were selective to androgen receptor (AR) and caused its inhibition. In-vitro data suggested 
that oxidative metabolites of FL 442 AB inhibited transcription of AR whereas oxidative 
metabolites of FL 425 AB were toxic. CYP 1A2 and CYP 2A6 were inhibited weakly (IC50=330 µM 
and 140 µM respectively) by FL 442 AB whereas CYP 1A2 was inhibited weakly (IC50=120 µM) by FL 
425 AB. No inhibition of CYP 3A4 was observed by FL 442 AB and FL 425 AB. So pre-clinical 
pharmacology data suggests that novel non-steroidal androgen receptor antagonists FL 442 AB 
and FL 425 AB have shown good metabolic stability.    
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1. INTRODUCTION 
The male sex hormones are called as androgens; androgen word originates from the two Greek 
words ‘andros’, man, and ‘gennan’, to produce. Testosterone and its active metabolite 5-α-
dihydrotestosterone (DHT) are most important endogenous androgens. Testis Leydig cells produce 
95% and adrenal gland produce 5% of testosterone. These hormones are involved in the penile 
and scrotum growth, body hair growth, thickness and darkness of skin, lower pitched voice 
(thickening of vocal cords), skeletal growth, prostate growth, stimulation and maintenance of 
sexual function in males (Bertram G. 2004). 
The effects of androgens are mediated by androgen receptor (AR), free AR form complexes with 
chaperone proteins in cytosol when testosterone or 5-DHT binds to the AR in the cytosol; 
chaperone proteins releases the receptor, then the structure is altered and receptor hormone 
complex is taken up by the nucleus. Various factors contribute to the AR function including basal 
transcription machinery, chromatin remodeling and interactions with co-regulator proteins. The 
growth and spread of prostate cancer is dependent heavily on AR. So AR poses an important 
target for drugs against prostate cancer (Kaikkonen et al. 2009). 
Androgen receptor antagonists are developed to control the AR activation and proliferation of 
prostate cancer. Two major types of AR antagonists are steroidal and non-steroidal. Prostate 
cancer is most often converted into castration resistant state after the treatment with existing 
non-steroidal AR antagonists and no longer beneficial to treat. So it’s important to develop novel 
AR antagonists to inhibit AR effectively and to treat Prostate cancer efficiently (Chen et al. 2009; 
Poutiainen et al. 2012). 
In the current work, the structure and physiological functions of AR, its relation with prostate 
cancer and existing AR antagonists were reviewed in detail under literature review. Oxidative 
metabolism of two novel non-steroidal AR antagonists FL 442 AB and FL425 AB were studied in-
vitro under microsomal CYP incubation conditions to compare their stability and metabolites 
between mouse and human liver microsomes. Oxidative metabolites of FL 442 AB and FL 425 AB 
were also studied for their AR antagonistic response in-vitro. Three inhibition experiments were 
designed to study the inhibition of hepatic coumarin 7-hydroxylation (CYP 2A6), CYP 1A2 and CYP 
3A4 by FL 442 AB and FL 425 AB and to calculate IC50 values of these ligands. 
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2. LITERATURE REVIEW 
 
2.1 Androgen receptor 
Specific effects of androgens are managed by androgen receptor (AR), which is ligand activated 
transcription factor, and a part of nuclear receptor (NR) proteins super family (Tsai & O’Malley 
1994; Poutiainen et al. 2012). There are three classes of nuclear receptor (NR) super family; class I 
contains glucocorticoid, mineralocorticoid, estrogen, progesterone and androgen receptors, Class 
II contains peroxisome proliferator, farnesoid, liver oxysterol, and retinoid receptors and hybrid 
class consists of thyroid and vitamin D receptors. Androgen receptors (AR) belong to the class I of 
Nuclear Receptor (NR) super family (Rang et al. 2011). 
 
2.1.1 Structure and functional regions 
Nuclear receptor including AR consists of four functional regions, N-terminal regulatory domain 
(NTD), a DNA binding domain (DBD), hinge region (H), ligand binding domain (LBD) and C-terminal 
(C) (Figure 1). The DBD and LBDs of progesterone receptor (PR), estrogen receptor (ER), 
mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) are structurally similar in many 
ways to AR, but these steroid receptors have certain functional specificity (Li & Al-Azzawi 2009; 
Rang et al. 2011).  
Androgen receptor contains eight exons (A, B, C, D, E, F, G, and H). Exon A is responsible for 
transactivation and covers around 50% of the coding region, exons B and C are translated to 
binding domain of DNA and exons D-H to binding domain of hormones (Taplin 2007).  
 
 
 
NTD domain of AR consists of half coding sequence of AR and provides a place for the majority of 
AR transcriptional machinery and functioning of coregulators and acts as the primary mediator for 
androgen effects. NTD structure alters when it interacts with other proteins with DNA (Chmelar et 
al. 2007).  
 Figure 1: Androgen receptor functional regions (NTD: N-terminal regulatory domain, DBD: DNA 
binding domain, H: hinge region, LBD: Ligand binding domain, C: C-terminal 
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DNA binding domain (DBD) have two zinc finger domains and C terminal extension (Mader et al. 
1993). First zinc finger acts as a mediator for DNA identification through the interaction between 
certain base pairs so allowing the receptor to bind itself with DNA (Hard et al. 1990). Second zinc 
finger provides stability to this DNA receptor complex (Schoenmakers et al. 1999).  
Hinge region is present between the DBD and LBD and plays an important role in commanding the 
transactivation potential of the androgen receptor and also provides important sites for 
acetylation, phosphorylation and degradation (Zhou et al. 1995; Tanner et al. 2004). 
The ligand binding domain (LBD) facilitates and act as a mediator for the binding of androgenic 
ligands to AR. Ligands cause structural change in the LBD and bending of helix 12 back into the 
ligand-binding space (Li & Al-Azzawi 2009). Androgen receptor (AR) function is dependent on the 
co-operation between N-terminal and ligand binding site (Ikonen et al. 1997).  
C – Terminal domain is specific according to the class of nuclear receptor and ligand binding 
module is present on this domain (Rang et al. 2011).  
  
2.1.2 Physiological functions 
AR is expressed in various tissues including prostate, liver, central nervous system (CNS) and 
skeletal muscles. Prostate, adrenal gland and epididymis have highest levels of AR. Two types of 
effects are caused by the activation of AR, androgenic effects and anabolic effects. Effects that are 
associated with the reproductive tissues e.g. testis and seminal vesicles are known as androgenic 
effects whereas effects of androgen in muscles and bones are known as anabolic effects. Male 
sexual characteristics like hair growth, maintaining libido, sperm production, muscles strength, 
and erythropoiesis are developed and maintained by functional AR (Gao et al. 2005). 
Androgens exert their effects by acting on AR and are needed for the normal growth and functions 
of prostate gland (Roy et al. 1999). Testosterone is synthesized mostly in testis, then it is 
transported to target tissues where it is metabolized to active metabolite DHT by an enzyme 5α-
reductase (Figure 2 and 3).Testosterone is responsible for various effects in human body tissues. 
These different kinds of effects depend on the metabolism of testosterone to two active steroidal 
compounds, dihydrotestosterone (DHT) and estradiol. There are 2 forms of 5α-reductase: Type I 
and Type II. Type I is mostly present in skin, liver and bones whereas Type II is found in genitals in 
men and women. Dihydrotestosterone has stronger affinity to bind with androgen receptor and 
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activation of genetic expression (Brunton 2006). Binding of testosterone and DHT to androgen 
receptor produce biological effects and also induce AR transcriptional activity. This transcriptional 
activity is dependent on the coregulators and their interaction with androgen receptor (AR) and 
phosphorylation of AR and AR coregulators (Heinlein & Chang 2004).  
             
 
 Testosterone Dihydrotestosterone (DHT) 
Figure 2: Structures of testosterone and dihydrotestosterone (DHT) 
 
 
Figure 3: Mechanism to produce androgen dependent effects 
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2.1.3 AR interacting proteins 
AR function is regulated by the interaction with the several nuclear proteins. These proteins are 
divided into three classes: Components of general transcriptional machinery, coregulators 
(coactivators or corepressors) and specific transcription factors (Heemers & Tindall 2007).  
Coregulators acts as signaling linkage in receptors and transcriptional machinery. Coregulators are 
divided into co-activators, co-repressors, co-integrators and median protein complexes. Examples 
of co-activators are SRC-1, SRC-2 and SRC-3, PCAF, PBP, ARA70, L7/SPA, Trip-1, E6-AP, PGC-1 and 
SRA. Examples of co-repressors are NCoR, SMRT, SUNCoR and NURD. Examples of co-integrators 
and median protein complexes are CBP/p300 and DRIP/TRAP/SMCC respectively (Janne et al. 
2000).   
 
2.1.4 Role of AR in diseases 
There are various diseases which are associated with the mutations in AR for example androgen 
insensitivity syndrome (AIS), infertility, prostate cancer and Kennedy’s disease (Figure 4). 
 
 
Figure 4: AR associated diseases 
 
Androgen Receptor
(AR)
Androgen Insensitivity
Syndrome
Prostate cancer Infertility Kennedy’s disease
Mutations in AR
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Androgen Insensitivity syndrome (AIS) 
Mutations in the AR gene in individuals having 46, XY karyotype are believed to develop end-organ 
resistance to androgens (testosterone and dihydrotestosterone) called as androgen insensitivity 
syndrome (AIS) (Chang et al. 1995; Lee & Chang 2003). Persons with AIS have following peculiar 
features: external female genitalia, short blind ending vagina, absence of epididymides, vas 
deferens and seminal vesicles, absence of prostate, gynecomastia, no hairs on pubic and axillary 
regions. Levels of testosterone and lutenizing hormone rise in AIS showing resistance of androgen 
at hypothalamic-pituitary axis. Rise in testosterone levels also causes elevated levels of estrogens, 
resulted in development of more female features in AIS persons (Quigley et al 1995; Brinkmann 
2001).     
Kennedy’s disease 
Kennedy’s disease is also called X-linked spinal and bulbar muscular atrophy. Kennedy’s disease is 
a rare, incurable X-linked genetic progressive neuro-muscular degenerative disease. Degeneration 
of motor neurons is caused by the elevated number of CAG repeats encoding a polyglutamine 
stretch inside AR. Symptoms of this disease are proximal and bulbar weakness, muscular atrophy, 
fasciculations, gynecomastia and postural tremors (Ellerby et al. 1999; Sperfeld et al. 2002).   
 
2.2 Androgen receptor and prostate cancer 
According to National Cancer Institute USA, “Cancer is a term used for diseases in which abnormal 
cells divide without control and are able to invade other tissues. Cancer cells can spread to other 
parts of the body through the blood and lymph systems”.  Prostate cancer is one of the most 
prominent and lethal cancers in the world. Prostate cancer is the second most common cancer 
worldwide for males and the fifth most common overall (Ferlay et al. 2008).  
Prostate cancer is one of the most prevalent cancers in the United States and Europe. Diet, life 
style, genes and androgens are the major risk factors for prostate cancer (Nelson et al. 2003). Diet 
consists of meat, high animal fat, less vegetables and fruits are one of the culprits for the 
promotion of prostate cancer. Vegetables enriched with vitamin E and other antioxidants provide 
protection against prostate cancer (Chan & Giovannucci 2001).  
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Standard treatment of prostate cancer involves regular monitoring of cancer patients, surgical 
removal of prostate gland, radiation therapy involving external beam radiation, brachytherapy and 
alpha emitter radiation therapy, hormonal therapy, immune therapy or biologic therapy, and 
bisphosphonate therapy to reduce bone pain associated with prostate cancer (Figure 5.) (Prostate 
cancer treatment 2014).  
 
 
 
Figure 5: Standard treatment of prostate cancer (Prostate cancer treatment 2014).   
 
Prostate cancer growth and spread is dependent on androgens, which are one of the main 
regulators of these cellular proliferations (Agus et al. 1999). The prostate cancer can be treated by 
suppression of androgen receptors (AR) and administration of anti-androgens (Figure 6.) 
(Hellerstedt & Pienta 2002). So treatment for prostate cancer is relied on the methods involving 
the reduction in the circulating androgens and androgen controlled signaling by activating 
androgen receptor (AR). Methods involve the castration i.e. surgical and chemical castration. 
Surgical castration includes getting rid of testicles whereas chemical castration includes the 
treatment of prostate cancer by the administration of anti-androgens or androgen deprivation 
therapy (ADT) (Massard & Fizazi, 2011). These castration treatments can cause resistance and 
ultimately resulted into the increase in the cancer tumor cells, prostate specific antigen (PSA) and 
Treatment of 
Prostate cancer
Careful and active 
monitoring
Surgery
Radiation therapy
Hormone therapy
Chemotherapy
Biologic 
therapy/immunotherapy
Bisphosphonate therapy 
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androgens. This dangerous state of prostate cancer is called as ‘castration resistant prostate 
cancer (CRPC). Other treatment options are radiation and chemotherapy but these treatment 
options can’t be used alone. Androgen receptor antagonists and hormonal therapies are the main 
options for the treatment of prostate cancer (Ahmed et al. 2014). 
 
 
Figure 6: Hormone therapy for prostate cancer (Prostate cancer treatment 2014). 
 
Prostate specific antigen (PSA) is the most sensitive biomarker for the diagnosis of prostate cancer 
and to check and evaluate the therapy’s response. PSA is a glycoprotein, belongs to the kallikrein 
family of serum proteases. In normal conditions, PSA is released into the glandular ducts and 
causes the degeneration of high molecular weight proteins to stop the coagulation of the semen. 
During the proliferation of prostate cancer, abnormalities develop in the prostate ducts which 
causes the increased levels of PSA in extracellular space and ultimately into the blood circulation.  
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Diethylstilbestrol (DES) 
 
Figure 7 : Structure of Diethylstilbestrol 
 
Diethylstilbestrol is the oldest compound used for the treatment of prostate cancer (Figure 7). 
Mechanism of action of DES is to suppress the secretion of pituitary luteinizing hormone (LH) by 
causing the negative feedback effect on hypothalamus and pituitary gland. Estrogens increase the 
levels of sex hormone binding and prolactin secretion by pituitary gland. Estrogens decrease the 
testosterone production in the testes. VACURG trials initiated in 1960’s provided the data about 
the cardio-toxicity associated with the DES usage in 3 mg/day dose. DES associated cardiovascular 
side effects are decrease in antithrombin III, increase in production of coagulation factors I, II, VII, 
IX and X, hypofibrinolysis, and decreased plasminogen activator (Malkowickz 2001). 
        
2.3 Androgen receptor antagonists 
Androgen receptor antagonists (antiandrogens) are used for the treatment of prostate cancer; 
these drugs inhibit the binding of androgens to the androgen receptor or inhibit 5α-reductase. 
Anti-androgens can be classified into two main groups: steroidal and non-steroidal antiandrogens. 
The use of antiandrogens as monotherapy can be beneficial not only for the treatment of prostate 
cancer but to preserve function of gonads and improving the quality of reproductive life and bone 
demineralization (Miyamoto et al. 2004).   
2.3.1 Steroidal antiandrogens 
Examples of steroidal antiandrogens are progesterone analogues cyproterone acetate, and 
megestrol acetate (Figure 8). Steroidal antiandrogens work as antagonist at androgen receptor 
and agonist at progesterone receptors. Steroidal antiandrogens are not used now because of their 
potential side effects and low effectiveness (Miyamoto et al. 2004).  
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 Cyproterone acetate Megestrol acetate 
Figure 8: Structures of steroidal anti-androgens 
 
Cyproterone acetate (CPA) 
Cyproterone acetate (CPA) is a steroidal progesterone analogue. It is used for the treatment of 
prostate cancer because of its anti-androgenic properties. CPA is also used for the treatment of 
other diseases like acne, female hirsutism, and breast cancer in females, hyper sexuality and 
sexual deviation in males. CPA exerts its mechanism of action by inhibiting the peripheral actions 
of testosterone and suppressing the gonadotropin release through negative feedback on pituitary 
gland (Savidou et al 2006). Cyproterone acetate is administered at a dose of 100 mg twice daily 5-
7 days before LHRH analogue and used for 3-4 weeks (Mahler et al. 1998). CPA is believed to have 
good tolerability but cases of hepatic failure reported following its usage. The mechanism behind 
this hepatotoxicity is not well characterized. Hepatotoxicity decreases the overall survival period 
of prostate cancer patients (Kim et al. 2014). CPA causes various complications including 
cardiovascular complications, loss of libido, erectile dysfunction, gynecomastia and central 
nervous system effects (Miyamoto et al 2004).  
Megestrol acetate 
Progesterone derivative megestrol acetate is potent inhibitor of 5α-reductase so causing the 
inhibition of conversion of testosterone to its active metabolite i.e. dihydrotestosterone (DHT). It 
is used for the treatment of prostate cancer in men and effective dose is 8-10 mg daily along with 
1-2 mg/day of testosterone. Various studies have shown that the use of progesterone as 
treatment for prostate cancer and breast cancer caused significant decrease in elevated prostate-
specific antigen (PSA) (Kaore et al. 2012).   
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2.3.2 Non-steroidal anti-androgens 
In order to counter the adverse effects associated with the use of steroidal anti-androgen, non-
steroidal anti-androgens were developed. Examples of non-steroidal anti-androgens are 
nilutamide, flutamide, and bicalutamide (Figure 9.) (Chen 2009). Non-steroidal antiandrogens stop 
the binding of testosterone and Dihydrotestosterone (DHT) to androgen receptors (AR) 
(Hellerstedt & Pienta 2002). Non-steroidal antiandrogens are chemical derivatives of anilides. 
These agents stop binding of androgens i.e. testosterone and dihydrotestosterone to AR in CNS, 
which interferes the negative feedback of testosterone on gonadotropin release. Steroidal 
antiandrogens cause the decrease in the levels of testosterone whereas non-steroidal 
antiandrogens increase testosterone levels so causing less impairment in sexual desire and 
potency (Reid et al. 1999). Ezalutamide has been approved by FDA in August 2012 for the 
treatment of castration resistant prostate cancer (Ning et al. 2013).  
  
  
 
 Flutamide Nilutamide  
  
  Bicalutamide      Enzalutamide 
Figure 9: Structures of non-steroidal anti-androgens 
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Flutamide 
FDA approved flutamide in 1989 and it is normally combined with LHRH agonists for the treatment 
of advanced and metastatic prostate cancer (Helsen et al. 2014). Flutamide absorption from 
gastrointestinal tract is rapid. After metabolism, flutamide is converted to 2-hydroxyflutamide 
(active compound). Excretion is through renal route and half-life is around 5-6 hours.  Flutamide is 
administered at a dose of 250 mg, 3 times a day. Flutamide exerts its action by preventing the 
binding of DHT to its receptor and also causes the inhibition of translocation of DHT already 
attached to the receptor inside nuclei. Common side effects associated with the use of this drug 
are gynecomastia, breast pain, hot flashes, diarrhea, and liver disturbances (Mahler et al. 1998). 
Flutamide is usually administered with LHRH agonists and not administered as monotherapy to 
treat metastatic prostate cancer because EORTC trial explained that flutamide causes sexual 
infertility in men and has poor efficacy (Helsen et al. 2014).   
 
Nilutamide 
Nilutamide is an anti-androgenic drug that blocks the action of testosterone and 
dihydrotestosterone (DHT). Nilutamide can be considered as pure anti androgen because it shows 
negligible affinity for progesterone, estrogen, or glucocorticoid receptors. Nilutamide is usually 
administered in combination therapy with LHRH agonists in castrated patients. Nilutamide 
improves the quality of life in castrated patients (Harris et al. 1993). Nilutamide is almost 
completely absorbed through gastrointenstinal tract. It takes 2.8 hours to reach peak plasma 
concentration. Metabolism is extensive and nilutamide has long half-life (56 hours) which ensures 
its once daily dose. Nilutamide is usually administered at a dose of 300 mg single oral dose daily 
for one month and then 150 mg daily is administered for the treatment of metastatic prostate 
cancer. Nausea, vomiting, increase in hepatic transaminases, alcohol intolerance, hot flashes, 
gynecomastia and delayed adaptation to darkness are the drug associated adverse effects (Mahler 
et al. 1998). One 8.5 years follow up study has shown that nilutamide when combined with 
orchiectomy in advanced prostate cancer patients lead to the better survival and improved the 
quality of life relieving bone pain of these patients compared to orchiectomy and placebo 
(Dijkman et al. 1997).  
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Bicalutamide 
FDA approved this drug for the treatment of prostate cancer in 1995. Bicalutamide is the most 
common non-steroidal anti-androgen, currently used in the treatment of prostate cancer. 
Bicalutamide has better efficacy, longer elimination half-life and fewer side effects as compared to 
flutamide and nilutamide; it also has stronger connection with androgen receptor as compared to 
other first generation anti-androgens. Its half-life is almost one week and ensures its once daily 
dosage (Goa & Spencer 1998). Bicalutamide has good bioavailability and absorption through oral 
route. This drug has two types of enantiomers R and S. R enantiomer has anti-androgenic activity 
and elimination half-life of 7 days (Mahler et al. 1998). Approved daily doses of bicalutamide in 
complete androgen blockade is 50 mg and 150 mg is used as monotherapy. Molecular dynamics-
based simulations explained that attachment of bicalutamide to ligand binding part of AR causes 
the dislocation of helix 12 and deformity of the coactivator part which leads to formation of 
inactive complex (Osguthorpe & Hagler 2011; Helsen et al. 2014). Gynecomastia, hot flashes, liver 
disturbances, impotence, high blood pressure and muscle weakness are common side effects 
associated with the use of bicalutamide (Mahler et al. 2014).  
 
Enzalutamide (MDV3100) 
The drawbacks associated with the usage of first generation anti androgens include the 
development of resistance in advanced stage prostate cancer patients that resulted in the 
preclinical development of second generation antiandrogens. FDA approved enzalutamide in 
August 2012. It is different from first generation anti androgens because of its action on AR 
nuclear translocation, DNA binding and co-activator recruitment. This drugs binds strongly to the 
ligand binding domain of AR. Enzulatamide binds strongly to AR than bicalutamide but also causes 
the squeezing of tumor in xenograft models whereas bicalutamide only stopped tumor growth. 
Enzalutamide exhibited the decrease in PSA levels of more than 50% in 43-56% of patients 
according to different phase I and II trials (Wong et al. 2014). One international randomized phase 
3 clinical trial showed that enzalutamide extended the survival of metastatic castration resistant 
prostate cancer patients by median of 4.8 months and subsided the death risk by 37% versus 
placebo (Scher et al. 2012). 
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2.3.3 Novel non-steroidal androgen receptor antagonists FL 442 AB and FL 425 AB 
First generation of non-steroidal anti-androgens during the treatment of prostate cancer drop 
their potential to inhibit the androgen receptor (AR) and cancer is converted into ‘castration 
resistant’ so there is a dire need for novel androgen receptor antagonists. FL 442 AB (4-(3a, 4, 5, 6, 
7, 7a-hexahydro-benzo[d]isoxazol-3-yl)-2-(trifluoromethyl) benzonitrile) and FL425 AB (3-(4-nitro-
3-(trifluoromethyl) phenyl)-3a, 4, 5, 6, 7, 7a-hexahydrobenzo[d] isoxazole) are novel cycloalkane 
(d) isoxazole pharmacophoric fragment containing anti-androgens (Figure 10.). These recently 
developed anti-androgens act on the androgen receptor (AR) as effectively as or excelling than the 
most common non-steroidal anti-androgenic drug bicalutamide. These androgen receptor ligands 
(FL 442 AB and FL 425 AB) (Figure 8) have been synthesized by PhD Juha Pulkkinen and his 
coworkers in School of pharmacy, University of Eastern Finland (UEF) (Poutiainen et al. 2012).  
Preclinical pharmacology studies suggest that FL 442 AB action is specific to AR, expresses clear 
antiandrogenic activity and in prostate cancer cell models it shows the expression of mutated AR 
ligand binding domain (LNCaP) and amplified AR (VCaP). FL 442 AB has half-life of 8 hours 
according to pharmacokinetic data in mice. FL 442 AB can be compared with enzalutamide 
because it is equally efficacious for stoppage of prostate cancer cell proliferation as enzalutamide. 
FL442 maintains its antiandrogenic potential with enzalutamide-activated ARF876L (Poutiainen et 
al. 2014).  
There is limited information about the metabolic and inhibition potential aspects of these new 
ligands. Therefore it is required to get information about the metabolism and inhibition potential 
of these novel androgen receptor antagonists.  
 
 
                             FL 442 AB (C15H13N2F3O)                                        FL 425 AB (C14H13N2F3O3) 
 (295.1053) (315.0951) 
Figure 10: Chemical structures of novel androgen receptor antagonists 
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3. AIMS OF THE STUDY 
The prime objective of this study was to obtain information about the metabolism of two 
androgen receptor ligands FL 442 AB and FL 425 AB, and to study the inhibitory effect of these 
antagonists on different cytochrome enzymes (CYP 1A2 and CYP 3A4) 
Specific aims of this study were (Figure 11.): 
i. To get the basic laboratory practice for me. 
ii. To study the rate of disappearance of 1 µM FL 442 AB and FL 425 AB ligands in microsomal 
CYP incubation conditions. 
iii. To compare the rate of disappearance of these ligands between mice and human. 
iv. To generate mixture of metabolites of FL 442 AB and FL 425 AB and to study the effect of 
these mixtures on expression of androgen dependent genes in LNCAP and VCAP prostate 
cancer cell cultures. 
v. To study the inhibition of hepatic coumarin 7-hydroxylation (CYP2A6), 7-Ethoxyresorufin O-
deethylation (CYP 1A2), 7-benzyl-4-trifluoromethylcoumarin O-debenzylation (CYP 3A4)    
by FL 442 AB and FL 425 AB and determination of IC 50 values. 
 
 
 
Figure 11: Aims of the study 
 
Aims
Laboratory Practice
Rate of disappearance in CYP 
incubation conditions
Comparison of rate of disappearance
in mice and human
Generate mixture of metabolites
Inhibition of CYP 
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4. METHODOLOGY 
 
4.1 Materials 
4.1.1 Chemicals 
 1 M phosphate buffer (pH 7.4) 
 1 M and 100mM Tris HCl buffer (pH 7.4) Ultrapure by MP Biomedicals France 
 30% Trichloro acetic acid (TCA) by Sigma Aldrich Germany 
 1.6 M Glycine-NaOH buffer (pH 10.4) 
 NADPH regeneration system (prepared by laboratory technician)  
200 ml of NADPH regeneration system is composed of 178, 5 mg NADP, 645 mg citric acid, 
75 mL 0,5 M Tris HCl + 0,15 M KCl, 25 mL 0,1 M MgCl2, 25 mL 0,1 mM MnCl2 in 200 mL H2O.  
 0.1 mM and 10 mM coumarin (in ethanol) 
 1 mM and 10 mM 7-Hydroxycoumarin 
 Methanol 
 Ethanol (99.5%) by Altia Oy Finland 
 Acetonitrile (HPLC grade) 
 Dichloromethane 
 20 mM Tranylcyclopropylamine in DMSO 
 1 mM 7-ethoxyresorufin in DMSO 
 100 µM Resorufin 
 10 mM 7-benzyl 4 trifluoromethylcoumarin (BFC) 
 0.2 mM 7-Hydroxy-4-trifluoromethylcoumarin (HFC) 
 Stop reagent (80% Acetonitrile/20% 0.5 M Tris HCl) 
 Purified Water (H2O) MAXIMA USF ELGA instrument at 18.2 MΩ. 
 Androgen receptor antagonists FL 442 AB and FL 425 AB 
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4.1.2 Biological Material 
Pig liver samples were obtained from untreated female pigs that were used for practicing surgical 
procedures at the University of Kuopio. DBA/2N/kuo mice were obtained from the National 
Laboratory Animal Center, Kuopio University. Liver microsomes were prepared from the animals 
as described previously (Lang et al., 1981). Human liver samples were obtained from patients 
undergoing surgery to remove hepatic tumors. Liver samples were frozen in liquid nitrogen and 
stored at -70oC. Only tumor-free tissues were used for the experiments. Baculovirus-insect cell-
expressed human CYP1A2 and CYP3A4 were purchased from BD Biosciences Discovery Lab ware 
(Bedford, MA, USA) 
4.1.3 Instruments 
 VICTOR 2TM plate counter fluorescence spectrophotometer (Perkin Elmer Life Sciences, 
Wallac, Finland) 
 Agilent 1290 series rapid resolution LC system (Agilent technologies, Waldbronn, Germany) 
 Agilent 6540 Q-TOF MS (Agilent Technologies, Palo Alto, CA, USA) 
 Centrifuge multifuge 3L-R 
 
4.1.4 Ethical considerations 
The Ethics Committee for Animal Experiments, University of Kuopio approved the animal tissue 
samples. The use of surplus human tissue of patients undergoing surgery to remove hepatic 
tumors was approved by the Ethics Committee of the University of Oulu. 
 
4.2 Enzyme assays 
4.2.1 Laboratory training 
Training of coumarin 7-hydroxylation 
Coumarin 7-hydroxylation was determined through 1 mL mixture containing 100 µL 1 M 
phosphate buffer pH 7.4, 10 µL 0.1 mM coumarin, 5 µL human liver microsomes and 400 µL 
NADPH regenerating system. This mixture was incubated at 37oC and 100 µL samples stopped by 
20 µL 30 % TCA at time points 5, 10, 30, 40, 50, 60, 70 and 80 minutes. Three blank samples did 
not contain either microsomes, coumarin or NADPH and were done otherwise similarly. 140 µL 1.6 
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M Glycin-NaOH buffer pH 7.4 was added to  the samples and  measured with Victor multiplate 
reader using excitation 350 nm and emission 450 nm.  
 
Training of inhibition of coumarin 7-hydroxylation 
Laboratory training about inhibition was performed by making reaction mixture and inhibition by 
100 µL compound mixture each containing 5 µL 1 M Tris HCl pH 7.4, 1 µL 250 µM coumarin, 5 µL 
pig liver microsomes and 25 µL NADPH regenerating system. 5 µL 20% DMSO also added in 
reaction mixture. Tranylcyclopropylamine was used as an inhibitory compound and 5 µL serial 
dilutions (20, 4, 0.8, 0.16, 0.032, 0.0064, 0.00128 and 0 mM) tranylcyclopylamine were added in 
inhibition to the compound mixture separately. These mixtures were then pre incubated at 37oC 
for 10 min. Reaction was stopped after 20 minutes of incubation by addition of 10 µL 30% TCA. 
Two blank samples were used, one sample was without microsomes and tranylcyclopropylamine 
and other without coumarin and DMSO. Standards of 7-hydroxy coumarin (0, 10 nM, 25 nM, 50 
nM, 100 nM, 0.25 µM) 100 µL in volume were also added to multi-well plate wells. 140 µL 1.6 M 
Glycin-NaOH buffer pH 7.4 added to  the samples and  measured with Victor multiplate reader 
using excitation 350 nm and emission 450 nm.  
 
4.2.2 FL 442 AB and FL 425 AB oxidative metabolism 
CYP oxidative metabolism experiment was performed by making 1 mL mixture containing 100 µL 1 
M phosphate buffer pH 7.4, 10 µL 0.1 mM androgen ligand FL 442 AB or FL425 AB, 5 µL 
microsomes, and 485 µL purified water. 400 µL NADPH was added in the last to start the reaction 
and then incubated at 37oC. Three mouse liver (M1, M2 and M3) and two human liver (H1 and H2) 
microsomes were used in this experiment. 100 µL samples were taken to 300 µL acetonitrile (HPLC 
Grade) at time points 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 60 min, 70 min, 80 min. 
Three blank 200 µL samples did not contain either microsomes, androgen ligand or NADPH 
respectively. After 80 minutes reaction in blank sample tubes were stopped with 600 µL 
acetonitrile. Samples were then centrifuged for 10 min at 10,000 RPM. 300 µL supernatant was 
transferred to the Eppendorf tube. Evaporated samples were dissolved in 50% methanol, then 
stored at -70oC in refrigerator. Later these samples were analyzed (MS Analysis).  
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4.2.3 Production of oxidative metabolites of FL 442 AB and FL 425 AB to study their effect on AR 
response in-vitro  
To observe the effects of the oxidative metabolites of FL 442 AB and Fl425 AB on prostate cancer 
cell cultures LNCAP and VCAP, 5 ml reaction mixture was prepared for both androgen ligand 
containing 500 µL 1 M phosphate buffer pH 7.4, 50 µL 1 mM androgen ligand, 100 µL microsomes 
and 2350 µL of purified water. 2000 µL NADPH was added in the last to start the reaction and then 
incubated at 37oC for 2 hours. Three blank samples did not contain either microsomes, NADPH or 
androgen ligand respectively. 2.5 mL samples were transferred to 5 mL dichloromethane tubes, 
mixed and centrifuged for 5 min at 3000 RPM. Dichloromethane (lower phase) was transferred to 
another tube with the help of Pasteur pipettes. 5 mL dichloromethane was added to water phase, 
mixed and centrifuged again. Dichloromethane (lower phase) was transferred again to another 
tubes with the help of Pasteur pipettes. 0.5 mL sample was collected in Eppendorf tubes from the 
combined dichloromethane fraction and then evaporated. These samples were analyzed to check 
the level of antagonists and metabolites. In remaining samples 50 µL ethanol added, mixed and 
closed. Evaporated the samples and stored in refrigerator. Then analyzed the effects of these 
oxidative metabolites on LNCAP and VCAP prostate cancer cell cultures. 
Luciferase Reporter Assay 
One day before transfection, COS-1 cells (from ATCC) were seeded onto 24-well plates in 1 ml of 
DMEM (Dulbecco’s modified Eagle medium, Gibco) containing 10% dextran-charcoal-treated fetal 
bovine serum (FBS) and 0.25% (vol/vol) penicillin-streptomycin (Euroclone) at a density of 70 x 103 
cells/well. After medium change to DMEM containing 2.5% FBS, the cells were transfected for 24 h 
with pSG5-hAR (10 ng/well), corresponding luc reporter (100 ng/well) and internal control pCMVb 
(10 ng/well) by using TransIT-LT1 Transfection Reagent (Mirus Bio LCC). After the transfection 
(18h), the cells were exposed to vehicle (ethanol) alone, testosterone (10 nM) (100% activation). 
In the antagonism reporter assays, the cells were exposed simultaneously to the agonist reference 
compound (oxidative metabolites of FL 442 AB and FL 425 AB). After 18 h, cells were processed 
and luciferase activities and protein concentrations were measured and relative luciferase 
activities were calculated (Poutiainen et al. 2012).   
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4.2.4 Inhibition of hepatic coumarin 7-hydroxylation (CYP2A6) by FL 442 AB and IC 50 value 
determination 
To see the inhibition of hepatic coumarin 7-hydroxylations by these novel AR antagonists, serial 
dilutions of 10 mM (3.33, 1.11, 0.37, 0.12, 0.04, 0.13 and 0mM) of FL 442 AB were prepared in 
ethanol. 100 µL reaction sample consisted of 5 µL 1 M tris HCl pH 7.4, 1 µL 100 µM coumarin, 5 µL 
1/10 human liver microsomes, 1 µL ethanol and 63 µL purified water. Whereas 100 µL inhibition 
by compound sample had similar reagents as reaction sample except ethanol and in addition it 
contained 1 µL different concentrations of FL 442 AB. Two blank samples were used, one blank 
sample was without microsomes and FL 442 AB and other one was without coumarin and ethanol. 
This multi-well plate was kept in incubator for 10 min at 37oC and reaction was started by the 
addition of 25 µL NADPH in all samples and kept that plate in incubator for 20 min. Reaction was 
stopped by the addition of 10 µL 30% TCA.   Standards of 100 µL (0, 10 nM, 25 nM, 50 nM, 100 
nM, 0.25 µM) of 7-Hydroxy coumarin were added to multi-well plate wells. 140 µL 1.6 M Glycin-
NaOH buffer pH 7.4 was added to  the samples and  measured with Victor multiplate reader using 
excitation 350 nm and emission 450 nm. 
 
4.2.5 Inhibition of 7-ethoxyresorufin O-deethylation (CYP1A2) by FL 442 AB and FL 425 AB 
To see the inhibition of 7-ethoxyresorufin O-deethylation (CYP1A2) by FL 442 AB and FL 425 AB, 
serial dilutions of 10 mM (10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.156 mM) FL 442 AB and FL 425 AB 
were prepared in ethanol. 100 µL reaction sample consisted of 10 µL 1 M tris HCl pH 7.4, 0.6 µL 1 
mM 7-ethoxy resorufin, 1 µM recombinant CYP1A2 and 37.4 µL purified water. Whereas 100 µL 
inhibition by compound sample had similar reagents as reaction sample except 1 µL ethanol was 
replaced with 1 µL different concentrations of FL 442 AB and FL 425 AB. Two blank samples were 
used, one was without 7-ethoxy resorufin and other one was without NADPH. Reaction was 
started by adding 50 µL NADPH to samples. 50 µL water was added to the wells of blank 2. Multi-
well plate was then incubated for 30 minutes. 100 µL 100 mM Tris HCl pH 7.4 and 0.5 µM resorufin 
standard were added to standard wells.  Reaction was stopped with 110 µL 80% Acetonitrile/20% 
0.5 M Tris HCl and measured with Victor multiplate reader using excitation 350 nm and emission 
450 nm. 
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4.2.6 Inhibition of 7-benzyl-4-trifluoromethylcoumarin O-debenzylation (CYP3A4) by FL 442 AB 
and FL 425 AB 
To see the inhibition of 7-benzyl 4-trifluoromethylcoumarin O-debenzylation (CYP3A4) by FL 442 
AB and FL 425 AB, serial dilutions of 10 mM (10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.156mM) FL 442 
AB and FL 425 AB were prepared. 100 µL reaction sample consisted of 10 µL 1 M tris HCl pH 7.4, 
0.5 µL 10 mM BFC, 1 µM recombinant CYP 3A4 and 37.5 µL purified water. Whereas 100 µL 
inhibition by compound sample had similar reagents as reaction sample except 1 µL ethanol was 
replaced with 1 µL different concentrations of FL 442 AB and FL 425 AB. Two blank samples were 
used, one was without BFC and other one was without NADPH. Reaction was started by adding 50 
µL NADPH to wells of reaction and blank 1. 50 µL water was added to the wells of blank 2. Multi-
well plate was then incubated for 30 minutes. 100 µL 100 mM Tris HCl pH 7.4 and 0.5 µM HFC 
standards were added to standard wells.  Reaction was stopped with 110 µL 80% Acetonitrile/20% 
0.5 M Tris HCl and measured with Victor multiplate reader using excitation 350 nm and emission 
450 nm. 
 
4.2.7 HPLC-MS analysis 
The HPLC-MS of FL 442 AB and FL 425 AB were performed using an Agilent Zorbax SB-C18 column 
(2.1 x 50 mm, 1.8 µm particle size) together with an Agilent Infinity in-line filter (0.2 µm). The 
temperature of the column oven was 50°C and the injection volume was 5 µL. Methanol was used 
as organic phase and aqueous phase was 0.1% formic acid. A linear gradient from 20% to 90% in 5 
min was applied, followed by 2 min isocratic elution with 90% MeOH and column equilibration 
during 3 min, giving an injection cycle of 10 min. The eluent flow rate was 0.3 mL/min. The MS 
equipped with an AJS electrospray ionization (ESI) source was operated in positive ionization 
mode. Mass range of 100–1000 was acquired using the 2 GHz extended dynamic range mode. 
Capillary voltage was 3500 V and fragmentor voltage 100 V. Nitrogen was used as sheath gas and 
drying gas, the flow rates being 11 L/min at 350°C and 10 L/min at 325°C, respectively. The 
nebulizer was adjusted to 45 psi. Agilent reference mass solution (m/z 121.05087 and m/z 
922.00979) was used as lock mass. Argon was used as collision gas and the collision energy was 30 
V when acquiring the targeted MS/MS data. All the LC/MS (MS) data was acquired using Mass 
hunter (B.04.00) acquisition software. 
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4.2.8 Data analysis 
For HPLC-MS data, Agilent Mass hunter Qualitative Analysis (B.05.00) and Metabolite ID (B.04.00) 
software’s were used for the data processing and analysis of MS spectra. 
Inhibitory concentration (IC 50) value was determined using the following equation below. 
IC 50 = I / (V0/Vi -1)     OR     Vi/Vo = 1(1+ I/IC 50) 
I = Concentration of Inhibitor 
Vi = Reaction Rate with Inhibitor 
Vo = Reaction rate without Inhibitor 
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5. RESULTS 
5.1 Laboratory Training 
Laboratory training experiment about metabolism was designed to obtain the basic practical 
training for performing experiments with androgen receptor antagonists. For this purpose, two 
experiments were conducted with coumarin 7-hydroxylation catalyzed by pig liver microsomes. In 
the first experiment coumarin 7-hydroxylation was determined at time points 0-80 min. In the 
second experiment coumarin 7-hydroxylation was inhibited by tranylcyclopropylamine and its IC 50 
value was calculated.   
In first training experiment of coumarin CYP oxidative metabolism, non-fluorescent coumarin was 
converted to fluorescent 7-hydroxy coumarin. Fluorescence increased linearly as the 
concentration of 7-hydroxy coumarin increased (Figure 12). 
 
 
Figure 12: Standard line between concentration of 7-hydroxycoumarin and fluorescence 
 
Amount of 7-Hydroxy coumarin increased along with the incubation time gradually from 5 minutes 
to 80 minutes (figure 13 A).  The rate of reaction decreased gradually as coumarin converted into 
7-hydroxy coumarin with the increase in time from 5 minutes to 80 minutes (Figure 13 B). 
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Figure 13: The effect of incubation time on coumarin 7-hydroxylation, panel A represents the 
formed 7-hydroxycoumarin and panel B represents the rate of coumarin 7-hydroxylation at 
various incubation times 
 
 
Figure 14: Inhibition of hepatic coumarin 7-hydroxylation by tranylcyclopropylamine (Blue 
line=Experimental, Red line=Calculated) 
 
In the second training experiment, IC50 value of tranylcyclopropylamine for inhibition of hepatic 
coumarin 7-hydroxylation was 40 nM (Figure 14). 
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5.2 Stability and in vitro metabolites of FL 442 AB and FL 425 AB 
Incubations of FL 442 AB and FL 425 AB were made with two types of microsomes i.e. mouse and 
human liver microsomes, reaction was started by the addition of NADPH regeneration system and 
then LC-MS was used to check the rate of disappearance.  
Concentration of FL 442 AB was decreased to less than 50% in three types of mouse liver 
microsomes whereas concentration of FL 425 AB was decreased to less than 20% in mouse and 
less than 40% in two types of human liver microsomes (Figure 15 and 16). 
Half-life of FL 442 AB in CYP incubation conditions with three types of mouse liver microsomes was 
67, 60 and 64 minutes respectively. Whereas half-life of FL 425 AB in CYP incubation conditions 
with one mouse and two human liver microsomes was 22, 21 and 43 minutes respectively.      
 
Figure 15: Rate of disappearance of 1 µM FL 442 AB in CYP incubation conditions with mouse (M) 
liver microsomes (Blue: M1, Red: M2, Green: M3) 
 
 
Figure 16: Rate of disappearance of 1 µM FL 425 AB in CYP incubation conditions with human 
(H)/mouse (M) liver microsomes (Blue: M, Red: H1, Green: H2) 
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5.3 FL 442 and FL 425 oxidative metabolites 
To generate mixture of metabolites of FL 442 AB and FL 425 AB, human liver microsomes were 
used and starting concentration was 100 µM. It was observed that eight hydroxylation metabolites 
of FL 442 AB were formed. Metabolite 1 and metabolite 2 (RT=6,602 min and 6,606) were main 
metabolites of FL 442 AB and were covering 27.08% and 20.04% LC/MS peak areas respectively. 
Whereas all other metabolites were covering less than 15% of LC/MS peak areas (Table 1) (Figure 
17). 
Table 1: Retention times and accurate masses for the detected in vitro metabolites of FL 442 AB 
 Compound 
FL 442 AB 
RT(min) 
Accurate 
mass 
Exact 
mass 
DmD 
LC/MS 
Peak area 
% 
1 Hydroxylation (+O) 6,602 311,0999 311,1002 – 0,3 27,08 
2 Hydroxylation (+O) 6,606 311,1004 311,1002 0,2 20,04 
3 Hydroxylation (+O) 4,773 311,1011 311,1002 0,9 10,88 
4 Hydroxylation (+O) 5,29 311,0994 311,1002 – 0,8 5,68 
5 Hydroxylation (+O) 5,583 311,1 311,1002 – 0,2 7,45 
6 Hydroxylation (+O) 4,809 311,1002 311,1002 0 13,38 
7 Hydroxylation (+O) 5,295 311,1006 311,1002 0,4 8,02 
8 Hydroxylation (+O) 5,589 311,1004 311,1002 0,2 7,43 
 
 
Figure 17: In vitro metabolites of FL 442 AB and their peak areas 
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Six hydroxylation metabolites of FL 425 AB were formed. Metabolite 5 and 6 (RT=7,343 min and 
7,331) were main metabolites of FL 425 AB and were covering 23.30% and 26.08% LC/MS peak 
areas respectively. Whereas all other metabolites were covering less than 17% of LC/MS peak 
areas (Table 2) (Figure 18). 
 
Table 2: Retention times and accurate masses for the detected in vitro metabolites of FL 425 AB 
 Compound 
FL 425 AB 
RT (min) 
Accurate 
mass 
Exact 
mass 
DmD 
LC/MS 
peak area 
% 
1 Hydroxylation (+O) 5,561 331,0912 331,09 – 1,2 9,35 
2 Hydroxylation (+O) 5,559 331,0905 331,09 – 0,5 12,14 
3 Hydroxylation (+O) 6,361 331,0899 331,09 0,1 12,93 
4 Hydroxylation (+O) 6,359 331,0895 331,09 0,5 16,18 
5 Hydroxylation (+O) 7,343 331,0905 331,09 – 0,5 23,30 
6 Hydroxylation (+O) 7,331 331,0906 331,09 – 0,6 26,08 
 
 
 
Figure 18: In vitro metabolites of FL 425 AB and their peak areas 
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5.4 The effect of metabolites on AR response in vitro 
 
 
 
Figure 19: The effects of oxidative metabolites of FL 442 AB and FL 425 AB on AR response in-vitro 
 
FL442 AB oxidative metabolites inhibited the transcription of androgen receptor whereas when 
performed same analysis on FL 425 AB metabolites it was observed that cells died and the protein 
content of the reaction wells was less than half of the controls and cells were visibly loose and 
weak so metabolites were toxic.  
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5.5 Inhibition of CYP enzymes 
FL 442 AB inhibited weakly CYP2A6 and CYP1A2 whereas no inhibition of CYP3A4 was observed 
(Figures 20, 21, 22). IC-50 values are shown in table 3. 
 
 
 
Figure 20: Inhibition of hepatic coumarin 7-hydroxylation (CYP2A6) by FL 442 AB 
 
 
 
Figure 21: Inhibition of 7-ethoxyresorufin O-deethylation (CYP1A2) by FL 442 AB 
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7-Benzyl 4-trifluoromethylcoumarin O-debenzylation was inhibited below 0.5 µM FL 442 AB and 
then stimulated 2.5 times at 0.63 mM, at higher concentrations stimulation decreased.  
 
 
 
Figure 22: Inhibition of 7-benzyl 4-trifluoromethylcoumarin O-debenzylation (CYP3A4) by FL 442 AB 
 
FL 425 AB inhibited weakly CYP1A2 whereas CYP3A4 was not inhibited (Figures 23, 24). IC 50 
values are shown in table 3. 
 
 
 
Figure 23: Inhibition of 7-ethoxyresorufin O-deethylation (CYP1A2) by FL 425 AB 
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Figure 24: Inhibition of 7-benzyl 4-trifluoromethylcoumarin O-debenzylation (CYP3A4) by FL 425 AB 
 
Table 3: IC50 of FL 442 AB and FL 425 AB 
  Inhibited Reaction IC50 of FL 442 AB (µM) IC50 of FL 425 AB (µM) 
Coumarin 7-hydroxylation 330 Not performed 
7-ethoxyresorufin O-deethylation  (CYP1A2) 140 120 
7-benzyl-4 trifluoromethylcoumarin (CYP3A4) No inhibition No inhibition 
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6. DISCUSSION 
Androgen receptor (AR) is the crucial target in all forms of prostate cancer and androgen 
deprivation therapy (ADT) is currently the standard treatment for advanced stage prostate cancer. 
Use of ADT after certain period of time causes the conversion of prostate cancer to castration 
resistant prostate cancer. Thus, it becomes imperative to identify the underlying mechanisms that 
cause development of resistance. Also,  discovery of new drugs like enzalutamide that can directly 
attach and binds to AR seem to be promising to treat castration resistant prostate cancer which is 
still incurable (Chen et al. 2009).    
Two new non-steroidal AR antagonists FL 442 AB and its nitro analogue FL 425 AB were developed 
for this purpose. In the last two years, initial research studies on FL 442 AB have shown that it is 
selective and specific to AR and its AR binding efficiency is better than most commonly used AR 
antagonist bicalutamide (Gronemeyer et al. 2003; Poutiainen et al. 2012; Poutiainen et al. 2014).       
Cytochrome enzymes (CYP) play important role in metabolizing lipophilic xenobiotics. It’s 
important for the potential drugs to show metabolic stability during preclinical in vivo and in vitro 
testing.  Therefore, this research aimed to study the rate of disappearance of 1 µM FL 442 AB and 
FL 425 AB ligands in microsomal CYP incubation conditions and comparison of rate of 
disappearance of these ligands in mice and human. Incubation of FL 442 AB and FL 425 AB were 
done with mouse and human liver microsomes, reaction was initiated with NADPH and then LC-
MS was used to check the rate of disappearance. Concentration of FL 442 AB was decreased to 
less than 50% in three types of mouse liver microsomes. FL 425 AB concentration was decreased 
to less than 20% in mouse liver microsomes and less than 40% in two types of human liver 
microsomes. To generate mixture of metabolites of FL 442 AB and FL 425 AB, human liver 
microsomes were used and the starting concentration was 100 µM. It was observed that eight 
hydroxylation metabolites of FL 442 AB and six hydroxylation metabolites of FL 425 AB were 
formed with the addition of one oxygen molecule in parent compounds. Peaks and retention times 
of these metabolites were observed and analyzed by using LC-MS (Table 1 & 2). The results show 
that FL 442 AB and FL 425 AB have good metabolic stability. Oxidative metabolites of FL 442 AB 
and FL 425 AB were also investigated in-vitro for their effects on LNCAP and VCAP prostate cancer 
cell cultures and it was observed that these oxidative metabolites inhibited transcription of AR 
whereas metabolites of FL 425 AB were toxic. Three different assays were performed to study the 
inhibition of hepatic coumarin 7-hydroxylation (CYP2A6), 7-Ethoxyresorufin O-deethylation 
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(CYP1A2), 7-benzyl-4-trifluoromethylcoumarin O-debenzylation (CYP3A4) by FL 442 AB and FL 425 
AB and to determine IC 50 values. CYP1A2 and CYP2A6 were inhibited weakly (IC50=330 µM and 
140 µM respectively) by FL 442 AB whereas CYP1A2 was inhibited weakly (IC50=120 µM) by FL 425 
AB. No inhibition of CYP 3A4 was observed by FL 425 AB. Inhibition of CYP 3A4 was observed at 
Initial concentrations by FL 442 AB followed by substantial stimulation of and then inhibition at 
higher concentrations. These results explain that novel androgen receptor antagonists FL 442 AB 
and FL 425 AB have shown good metabolic stability during preclinical pharmacological evaluation.   
 
7. CONCLUSION 
Metabolic aspects and inhibition potential of novel AR antagonists FL 442 AB and FL 425 AB were 
studied by performing different enzyme assays. Following are the major findings: 
 FL 442 AB and FL 425 AB exhibited clear anti-androgenic activity. 
 Eight hydroxylation metabolites of FL 442 AB and six hydroxylation metabolites of FL 425 
AB were formed. 
 According to in-vitro data, oxidative metabolites of FL 442 AB inhibited transcription of AR.  
 According to in-vitro data, oxidative metabolites of FL 425 AB were toxic. 
 Initial inhibition and then stimulation of CYP3A4 was observed at higher concentrations by 
FL 442 AB  
 No inhibition of CYP3A4 was observed with FL 425 AB. 
 CYP1A2 and CYP2A6 were inhibited weakly by FL 442 AB 
 CYP1A2 was inhibited weakly by FL 425 AB 
 
Novel AR antagonists FL 442 AB and FL 425 AB have shown good metabolic stability and these 
compounds have shown weak inhibition potential for CYP enzymes.  However, further research 
studies on these compounds FL 442 AB and FL 425 AB are needful. 
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